Federica Cattani

Dr. Federica Cattani

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in British Journal of Radiology
Verified
Journal Article
Closed access
DZDario Zerini
Dario Zerini
BJB A Jereczek-Fossa
B A Jereczek-Fossa
CFC Fodor
C Fodor
FBF Bazzani
F Bazzani
AMA Maucieri
A Maucieri
ROR Orecchia
R Orecchia
To retrospectively evaluate external beam reirradiation (re-EBRT) delivered to the prostate/prostatic bed for local recurrence, after radical or adjuvant/salvage radiotherapy (RT). 32 patients received re-EBRT between February 2008 and October 2013. All patients had clinical/radiological local relapse in the prostate or prostatic bed and no distant metastasis. re-EBRT was delivered with selective RT technologies [stereotactic RT including CyberKnife(TM) (Accuray, Sunnyvale, CA); image-guidance and intensity-modulated RT etc.]. Toxicity was evaluated using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria. Biochemical control was assessed according to the Phoenix definition (NADIR + 2 ng ml(-1)). Acute urinary toxicity: G0, 24 patients; G1, 6 patients; G2, 2 patients. Acute rectal toxicity: G0, 28 patients; G1, 2 patients; and G2, 1 patient. Late urinary toxicity (evaluated in 30 cases): G0, 23 patients; G1, 6 patients; G2, 1 patient. Late renal toxicity: G0, 25 patients; G1, 5 patients. A mean follow-up of 21.3 months after re-EBRT showed that 13 patients were free of cancer, 3 were alive with biochemical relapse and 12 patients were alive with clinically evident disease. Four patients had died: two of disease progression and two of other causes. re-EBRT using modern technology is a feasible approach for local prostate cancer recurrence offering 2-year tumour control in about half of the patients. Toxicity of re-EBRT is low. Future studies are needed to identify the patients who would benefit most from this treatment. Our series, based on experience in one hospital alone, shows that re-EBRT for local relapse of prostate cancer is feasible and offers a 2-year cure in about half of the patients.

1 September 2016 in British Journal of Radiology
Verified
Journal Article
Closed access
GFGiovanni Fellin
Giovanni Fellin
MMMaria A Mirri
Maria A Mirri
LSLuigi Santoro
Luigi Santoro
BJBarbara Alicja Jereczek-Fossa
Barbara Alicja Jereczek-Fossa
CDClaudio Divan
Claudio Divan
RORoberto Orecchia
Roberto Orecchia
Objective:Low Dose Rate Brachytherapy (LDR-BT) in localized prostate cancer is available since 15 years in Italy. We realized the first national multicentre and multidisciplinary data collection to evaluate LDR-BT practice, given as monotherapy, and outcome in terms of biochemical failure.Methods:Between 5/1998 and 12/2011, 2237 early stage prostate cancer patients from 11 Italian Community and Academic Hospitals were treated with Iodine-125 (125I) or Palladium-103 (103Pd) LDR-BT as monotherapy and followed-up for at least two years. 125I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume (D90) was 145 Gy; the mean V100 (target volume receiving 100% of prescribed dose) equals 91.1%. Biochemical failure free survival (BFFS), Disease specific survival (DSS) and Overall Survival (OS) were estimated using Kaplan-Meier method. Log-Rank test and multivariable Cox regression were used to evaluate relationship of covariates with outcomes.Results:Median follow-up time was...

1 September 2011 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
BJBarbara Alicja Jereczek-Fossa
Barbara Alicja Jereczek-Fossa
DZDario Zerini
Dario Zerini
CFCristiana Fodor
Cristiana Fodor
LSLuigi Santoro
Luigi Santoro
RCRaffaella Cambria
Raffaella Cambria
RORoberto Orecchia
Roberto Orecchia

1 September 2021 in Journal of Cardiovascular Computed Tomography
Verified
Journal Article
Closed access
Edoardo ConteEdoardo Conte
Edoardo Conte
SMSaima Mushtaq
Saima Mushtaq
CCCorrado Carbucicchio
Corrado Carbucicchio
GPGaia Piperno
Gaia Piperno
VCValentina Catto
Valentina Catto
DADaniele Andreini
Daniele Andreini

1 October 2017 in British Journal of Radiology
Verified
Journal Article
Closed access
DCDelia Ciardo
Delia Ciardo
BJBarbara Alicja Jereczek-Fossa
Barbara Alicja Jereczek-Fossa
GPGiuseppe Petralia
Giuseppe Petralia
GTGiorgia Timon
Giorgia Timon
DZDario Zerini
Dario Zerini
RORoberto Orecchia
Roberto Orecchia
Purpose: The integration of CT and multiparametric MRI (mpMRI) is a challenging task in high-precision radiotherapy for prostate cancer. A simple methodology for multimodal deformable image registration (DIR) of prostate cancer patients is presented. Methods: CT and mpMRI of 10 patients were considered. Organs at risk and prostate were contoured on both scans. The dominant intraprostatic lesion was additionally delineated on MRI. After a preliminary rigid image registration, the voxel intensity of all the segmented structures in both scans except the prostate was increased by a specific amount (a constant additional value, A), in order to enhance the contrast of the main organs influencing its position and shape. 70 couples of scans were obtained by varying A from 0 to 800 and they were subsequently non-rigidly registered. Quantities derived from image analysis and contour statistics were considered for the tuning of the best performing A. Results: A = 200 resulted the minimum enhancement value required to obtain statistically significant superior registration results. Mean centre of mass distance between corresponding structures decreases from 7.4 mm in rigid registration to 5.3 mm in DIR without enhancement (DIR-0) and to 2.7 mm in DIR with A = 200 (DIR-200). Mean contour distance was 2.5, 1.9 and 0.67 mm in rigid registration, DIR-0 and DIR-200, respectively. In DIR-200 mean contours overlap increases of +13 and +24% with respect to DIR-0 and rigid registration, respectively. Conclusion: Contour propagation according to the vector field resulting from DIR-200 allows the delineation of dominant intraprostatic lesion on CT scan and its use for high-precision radiotherapy treatment planning. Advances in knowledge: We investigated the application of a B-spline, mutual information-based multimodal DIR coupled with a simple, patient-unspecific but efficient contrast enhancement procedure in the pelvic body area, thus obtaining a robust and accurate methodology to transfer the functional information deriving from mpMRI onto a planning CT reference volume.

1 April 2006 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
FCFederica Cattani
Federica Cattani
AVAndrea Vavassori
Andrea Vavassori
APAlfredo Polo
Alfredo Polo
ERElena Rondi
Elena Rondi
RCRaffaella Cambria
Raffaella Cambria
GTGiampiero Tosi
Giampiero Tosi